Exact Sciences announced the presentation of new data further reinforcing the utility of its Oncotype DX Breast Recurrence Score®? test at the 19thSt. Gallen International Breast Cancer Conference in Vienna, Austria.
A UK study explored the benefits of shifting the testing point to the pre-surgery setting by utilizing Oncotype DX on breast cancer core biopsy samples instead of surgical specimens. This multi-centre, prospective, randomized controlled trial (PreDX) included 341 patients eligible for Oncotype DX testing across 17 breast cancer units. The findings showed that testing on core biopsy led to a reduction in time to treatment outcome, including a clinically meaningful eight-day reduction in time from surgery to start of adjuvant treatment.
In addition, testing before surgery improved the patient experience, with a significant reduction in anxiety and depression scores. The test success rate on the core biopsy was 99.1%, confirming previous studies which showed that core biopsy samples produce Recurrence Score®? results highly concordant with those from surgical specimens and that Recurrence Score result distributions remain consistent between core biopsy and surgical samples when assessed by patient age (The Oncotype DX Breast Rec recurrence Score test is designed to facilitate personalized clinical decisions by providing information about the biology of an individual breast cancer, with the potential to deliver financial benefits for healthcare systems. The test was first made available to patients in 2004, and over 1.5 million patients around the world have benefited from it.
It is incorporated in major breast cancer treatment guidelines, including those of the European Society for Medical Oncology (ESMO) and the St. Gallen International Breast Cancer conference, as well as the American Society of Clinical Oncology (ASCO®?) and the National Comprehensive Cancer Network (NCCN®?) in the U.S.
